Earlier today (13/02/2020) the Food Standards Agency (FSA) released a statement in which they set a deadline for the CBD industry and provided advice for consumers.

The FSA statement explained that after March 31 2021, only products which have submitted a valid application will be allowed to remain on the market. In addition to this, the FSA advised those who are pregnant or breastfeeding to not consume CBD products.

The statement also included a quote from Chief Executive of the Food Standards Agency, Emily Miles, in which she said:

“The actions that we’re taking today are a pragmatic and proportionate step in balancing the protection of public health with consumer choice. It is now up to the industry to supply this information so that the public can be reassured that CBD is safe and what it says it is.”

The FSA advised people who are taking any medication to not consume any CBD products. We are proud to say, CBDLife has always given the correct advice in regards to the points raised by the FSA as we take consumer safety very seriously.

The Cannabis Trades Association (CTA) have responded with their own press release stating that although they “duly welcome a Route to Compliance for the industry and its members, we are still of the opinion that natural (not isolates or synthetic forms) CBD products do not fall under the scope of the Novel Food schedule.”

In regards to the FSA safety concerns, the CTA agree that CBD as a food supplement should not be administered in high daily doses, suggesting CBD consumers should not administer more than 200mg, as approved by the MHRA in 2016.

Although the CTA do not agree in full with all that the FSA has proposed, they believe it is a “positive step towards ensuring consumer safety and that CBD will be on the shelves for many years to come.”

Read the full CTA Press Release here: LINK